Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-011731
Filing Date
2025-05-20
Accepted
2025-05-20 16:30:30
Documents
42
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 288694
2 EX-31.1 ex31-1.htm EX-31.1 10934
3 EX-32.1 ex32-1.htm EX-32.1 4468
  Complete submission text file 0001641172-25-011731.txt   1950012

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE glsi-20250331.xsd EX-101.SCH 16772
5 XBRL CALCULATION FILE glsi-20250331_cal.xml EX-101.CAL 23183
6 XBRL DEFINITION FILE glsi-20250331_def.xml EX-101.DEF 73286
7 XBRL LABEL FILE glsi-20250331_lab.xml EX-101.LAB 152522
8 XBRL PRESENTATION FILE glsi-20250331_pre.xml EX-101.PRE 129865
44 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 169150
Mailing Address 3992 BLUEBONNET DR, BUILDING 14 STAFFORD TX 77477
Business Address 3992 BLUEBONNET DR, BUILDING 14 STAFFORD TX 77477 203-434-3290
Greenwich LifeSciences, Inc. (Filer) CIK: 0001799788 (see all company filings)

EIN.: 205473709 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39555 | Film No.: 25969253
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)